Ovarian VEGF165b expression regulates follicular development, corpus luteum function and fertility

Reproduction

Volumn 143, Issue 4, 2012, Pages 501-511

  Qiu, Y ^a   Seager, M ^a   Osman, A ^a   Castle Miller, J ^a   Bevan, H ^a   Tortonese, D J ^a   Murphy, D ^b   Harper, S J ^a   Fraser, H M ^c   Donaldson, L F ^a   Bates, D O ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VASCULOTROPIN 165B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALLITRICHINAE; CORONA RADIATA (OOCYTE); CORPUS LUTEUM FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FERTILITY; GRANULOSA CELL; IMMUNOHISTOCHEMISTRY; MATING; MOUSE; NONHUMAN; OVARY FOLLICLE DEVELOPMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; THECA CELL;

ANIMALS; CALLITHRIX; DOWN-REGULATION; FEMALE; FERTILITY; HUMANS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; OVARY; PREGNANCY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

MAMMALIA; MARMOSETS; MUS; MUS MUSCULUS; PRIMATES; RADIATA;

EID: 84860468850     PISSN: 14701626     EISSN: 17417899     Source Type: Journal    
DOI: 10.1530/REP-11-0091     Document Type: Article

References (48)

1. Abramoff MD, Magelhaes PJ & Ram SJ 2004 Image processing with ImageJ. Biophotonics International 11 36-42.
2. Artac RA, McFee RM, Smith RA, Baltes-Breitwisch MM, Clopton DT & Cupp AS 2009 Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary. Biology of Reproduction 81 978-988. (doi:10.1095/biolreprod.109.078097)
3. Bates DO, Cui TG, Doughty JM, Winkler M, Sugiono M, Shields JD, Peat D, Gillatt D & Harper SJ 2002 VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Research 62 4123-4131. (Pubitemid 34791084)
4. Bates DO, MacMillan PP, Manjaly JG, Qiu Y, Hudson SJ, Bevan HS, Hunter AJ, Soothill PW, Read M, Donaldson LF et al. 2006 The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term. Clinical Science 110 575-585. (doi:10.1042/CS20050292)
5. Cebe Suarez S, Pieren M, Cariolato L, Arn S, Hoffmann U, Bogucki A, Manlius C, Wood J & Ballmer-Hofer K 2006 A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cellular and Molecular Life Sciences 63 2067-2077. (doi:10.1007/s00018- 006-6254-9)
6. Charnock-Jones DS, Sharkey AM, Rajput-Williams J, Burch D, Schofield JP, Fountain SA, Boocock CA & Smith SK 1993 Identification and localization of alternately spliced mRNAs for vascular endothelial growth factor in human uterus and estrogen regulation in endometrial carcinoma cell lines. Biology of Reproduction 48 1120-1128. (doi:10.1095/biolreprod48.5.1120)
7. Chu S, Mamers P, Burger HG & Fuller PJ 2000 Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. Journal of Clinical Endocrinology and Metabolism 85 1200-1205. (doi:10.1210/jc.85.3.1200)
8. Duncan WC, van den Driesche S & Fraser HM 2008 Inhibition of vascular endothelial growth factor in the primate ovary up-regulates hypoxia-inducible factor-1alpha in the follicle and corpus luteum. Endocrinology 149 3313-3320. (doi:10.1210/en.2007-1649)
9. Fan X, Krieg S, Kuo CJ, Wiegand SJ, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC & Nayak NR 2008 VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB Journal 22 3571-3580. (doi:10.1096/fj.08-111401)
10. Fraser HM & Duncan WC 2009 SRB Reproduction, Fertility and Development Award Lecture 2008. Regulation and manipulation of angiogenesis in the ovary and endometrium. Reproduction, Fertility, and Development 21 377-392. (doi:10.1071/RD08272)
11. Fraser HM, Dickson SE, Lunn SF, Wulff C, Morris KD, Carroll VA & Bicknell R 2000 Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology 141 995-1000. (doi:10.1210/en.141.3.995)
12. Fraser HM, Wilson H, Silvestri A, Morris KD & Wiegand SJ 2008 The role of vascular endothelial growth factor and estradiol in the regulation of endometrial angiogenesis and cell proliferation in the marmoset. Endocrinology 149 4413-4420. (doi:10.1210/en.2008-0325)
13. Harper SJ & Bates DO 2008 VEGF-A splicing: the key to anti-angiogenic therapeutics? Nature Reviews. Cancer 8 880-887. (doi:10.1038/nrc2505)
14. Hua J, Spee C, Kase S, Rennel ES, Magnussen AL, Qiu Y, Varey A, Dhayade S, Churchill AJ, Harper SJ et al. 2010 Recombinant human VEGF165b inhibits experimental choroidal neovascularization. Investigative Ophthalmology & Visual Science 51 4282-4288. (doi:10.1167/iovs.09-4360)
15. Kamat BR, Brown LF, Manseau EJ, Senger DR & Dvorak HF 1995 Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development. American Journal of Pathology 146 157-165.
16. Konopatskaya O, Churchill AJ, Harper SJ, Bates DO & Gardiner TA 2006 VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Molecular Vision 12 626-632. (Pubitemid 43786776)
17. Kraaij R, Verhoef-Post M, Grootegoed JA & Themmen AP 1998 Alternative splicing of follicle-stimulating hormone receptor pre-mRNA: cloning and characterization of two alternatively spliced mRNA transcripts. Journal of Endocrinology 158 127-136. (doi:10.1677/joe.0.1580127)
18. Magnussen A, Rennel ES, Hua J, Bevan HS, Beazley-Long N, Lehrling C, Gammons M, Floege J, Harper SJ, Agostini HTet al. 2010 VEGF-A165b is cytoprotective and anti-angiogenic in the retina. Investigative Ophthalmology & Visual Science 51 4273-4281. (doi:10.1167/iovs.09-4296)
19. Mandai M, Konishi I, Kuroda H, Fukumoto M, Komatsu T, Yamamoto S, Nanbu K, Rao CV & Mori T 1997 Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. European Journal of Cancer 33 1501-1507. (doi:10.1016/S0959-8049(97)00166-4)
20. McFee RM, Artac RA, Clopton DT, Smith RA, Rozell TG & Cupp AS 2009 Inhibition of vascular endothelial growth factor receptor signal transduction blocks follicle progression but does not necessarily disrupt vascular development in perinatal rat ovaries. Biology of Reproduction 81 966-977. (doi:10.1095/biolreprod.109.078071)
21. Merdzhanova G, Gout S, Keramidas M, Edmond V, Coll JL, Brambilla C, Brambilla E, Gazzeri S & Eymin B 2010 The transcription factor E2F1 and the SR protein SC35 control the ratio of pro-angiogenic versus antiangiogenic isoforms of vascular endothelial growth factor-A to inhibit neovascularization in vivo. Oncogene 29 5392-5403. (doi:10.1038/onc.2010.281)
22. Myers M, Britt KL, Wreford NG, Ebling FJ & Kerr JB 2004 Methods for quantifying follicular numbers within the mouse ovary. Reproduction 127 569-580. (doi:10.1530/rep.1.00095)
23. Nowak DG, Woolard J, Amin EM, Konopatskaya O, Saleem MA, Churchill AJ, Ladomery MR, Harper SJ & Bates DO 2008 Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by known splicing and growth factors. Journal of Cell Science 121 3487-3495. (doi:10.1242/jcs. 016410)
24. Nowak DG, Amin EM, Rennel ES, Hoareau-Aveilla C, Gammons M, Damodoran G, Hagiwara M, Harper SJ, Woolard J, Ladomery MR et al. 2010 Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. Journal of Biological Chemistry 285 5532-5540. (doi:10.1074/jbc.M109.074930)
25. Otten AD, Sanders MM & McKnight GS 1988 The MMTV LTR promoter is induced by progesterone and dihydrotestosterone but not by estrogen. Molecular Endocrinology 2 143-147. (doi:10.1210/mend-2-2-143)
26. Parrott JA & Skinner MK 1998 Developmental and hormonal regulation of keratinocyte growth factor expression and action in the ovarian follicle. Endocrinology 139 228-235. (doi:10.1210/en.139.1.228)
27. Pedersen T & Peters H 1968 Proposal for a classification of oocytes and follicles in the mouse ovary. Journal of Reproduction and Fertility 17 555-557. (doi:10.1530/jrf.0.0170555)
28. Pepper MS, Baetens D, Mandriota SJ, Di Sanza C, Oikemus S, Lane TF, Soriano JV, Montesano R & Iruela-Arispe ML 2000 Regulation of VEGF and VEGF receptor expression in the rodent mammary gland during pregnancy, lactation, and involution. Developmental Dynamics 218 507-524. (doi:10.1002/1097-0177(200007) 218:3<507::AID-DVDY1012>3.0.CO;2-5)
29. Pritchard-Jones RO, Dunn DB, Qiu Y, Varey AH, Orlando A, Rigby H, Harper SJ & Bates DO 2007 Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma. British Journal of Cancer 97 223-230. (doi:10.1038/sj.bjc.6603839)
30. Qiu Y, Bevan H, Weeraperuma S, Wratting D, Murphy D, Neal CR, Bates DO & Harper SJ 2008 Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB Journal 22 1104-1112. (doi:10.1096/fj.07-9718com)
31. Ravindranath N, Little-Ihrig L, Phillips HS, Ferrara N & Zeleznik AJ 1992 Vascular endothelial growth factor messenger ribonucleic acid expression in the primate ovary. Endocrinology 131 254-260. (doi:10.1210/en.131.1.254)
32. Rennel E, Waine E, Guan H, Schuler Y, Leenders W, Woolard J, Sugiono M, Gillatt D, Kleinerman E, Bates D et al. 2008a The endogenous antiangiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. British Journal of Cancer 98 1250-1257. (doi:10.1038/sj.bjc.6604309)
33. Rennel ES, Hamdollah-Zadeh MA, Wheatley ER, Magnussen A, Schuler Y, Kelly SP, Finucane C, Ellison D, Cebe-Suarez S, Ballmer-Hofer K et al. 2008b Recombinant human VEGF165b protein is an effective anti-cancer agent in mice. European Journal of Cancer 44 1883-1894. (doi:10.1016/j.ejca.2008.05.027)
34. Schumacher VA, Jeruschke S, Eitner F, Becker JU, Pitschke G, Ince Y, Miner JH, Leuschner I, Engers R, Everding AS et al. 2007 Impaired glomerular maturation and lack of VEGF165b in Denys-Drash syndrome. Journal of the American Society of Nephrology 18 719-729. (doi:10.1681/ASN.2006020124)
35. Shweiki D, Itin A, Neufeld G, Gitay-Goren H & Keshet E 1993 Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. Journal of Clinical Investigation 91 2235-2243. (doi:10.1172/JCI116450)
36. Taylor RN & Mueller MD 2004 Anti-angiogenic treatment of endometriosis: biochemical aspects. Gynecologic and Obstetric Investigation 57 54-56. (Pubitemid 38186438)
37. Utsunomiya T, Tanaka T, Utsunomiya H & Umesaki N 2008 A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis. International Journal of Oncology 32 991-1000.
38. Varey AH, Rennel ES, Qiu Y, Bevan HS, Perrin RM, Raffy S, Dixon AR, Paraskeva C, Zaccheo O, Hassan AB et al. 2008 VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. British Journal of Cancer 98 1366-1379. (doi:10.1038/sj.bjc.6604308)
39. Wagner KU, McAllister K, Ward T, Davis B, Wiseman R & Hennighausen L 2001 Spatial and temporal expression of the Cre gene under the control of the MMTV-LTR in different lines of transgenic mice. Transgenic Research 10 545-553. (doi:10.1023/A:1013063514007)
40. Wang XN & Greenwald GS 1993 Hypophysectomy of the cyclic mouse. II. Effects of follicle-stimulating hormone (FSH) and luteinizing hormone on folliculogenesis, FSH and human chorionic gonadotropin receptors, and steroidogenesis. Biology of Reproduction 48 595-605. (doi:10.1095/biolreprod48. 3.595)
41. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, Cui TG, Sugiono M, Waine E, Perrin R et al. 2004 VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Research 64 7822-7835. (doi:10.1158/0008-5472.CAN-04-0934)
42. Woolard J, Bevan HS, Harper SJ & Bates DO 2009 Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation 16 572-592. (doi:10.1080/10739680902997333)
43. Wulff C, Wiegand SJ, Saunders PT, Scobie GA & Fraser HM 2001 Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology 142 3244-3254. (doi:10.1210/en.142.7.3244)
44. Wulff C, Wilson H, Wiegand SJ, Rudge JS & Fraser HM 2002 Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2. Endocrinology 143 2797-2807. (doi:10.1210/en.143.7.2797)
45. Yan Z, Weich HA, Bernart W, Breckwoldt M & Neulen J 1993 Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. Journal of Clinical Endocrinology and Metabolism 77 1723-1725. (doi:10.1210/jc.77.6.1723)
46. Zimmermann RC, Xiao E, Husami N, Sauer MV, Lobo R, Kitajewski J & Ferin M 2001 Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. Journal of Clinical Endocrinology and Metabolism 86 768-772. (doi:10.1210/jc.86.2.768)
47. Zimmermann RC, Xiao E, Bohlen P & Ferin M 2002 Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. Endocrinology 143 2496-2502. (doi:10.1210/en.143.7.2496)
48. Zimmermann RC, Hartman T, Kavic S, Pauli SA, Bohlen P, Sauer MV & Kitajewski J 2003 Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. Journal of Clinical Investigation 112 659-669. (doi:10.1172/JCI18740)